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Introduction: Lysosomal cathepsins have been reported to contribute to Osteoarthritis (OA) pathophysiology
due to their increase in pro-inflammatory conditions. Given the causal role of cathepsins in OA, monitoring their
specific activity could provide means for assessing OA severity. To this end, we herein sought to assess a cathepsin
activity-based probe (ABP), GB123, in vitro and in vivo.
Methods: Protein levels and activity of cathepsins B and S were monitored by immunoblot analysis and GB123
labeling in cultured primary chondrocytes and conditioned media, following stimuli with tumor necrosis factor
alpha (TNFα) and/or Interleukin 1 beta (IL-1β). Similarly, cathepsin activity was examined in sections of intact
cartilage (IC) and degraded cartilage (DC) regions of OA. Finally, synovial fluid (SF) and serum from donors with
no signs of diseases, early OA, late OA and rheumatoid arthritis (RA) patients were analyzed with GB123 to detect
distinct activity levels of cathepsin B and S.
Results: Cathepsin activity in cell lysates, conditioned media explants and DC sections showed enhanced
enzymatic activity of cathepsins B and S. Further histological analysis revealed that cathepsin activity was found
higher in superficial zones of DC than in IC. Examining serum and SF revealed that cathepsin B is significantly
elevated with OA severity in serum and SF, yet levels of cathepsin S are more correlated with synovitis and RA.
Conclusions: Based on our data, cathepsin activity monitored by ABPs correlated well with OA severity and joint
inflammation, directing towards a novel etiological target for OA, which possesses significant translational potential
in developing means for non-invasive detection of early signs of OA.Introduction
Osteoarthritis (OA) is an extremely common type of de-
generative joint disease and is a major cause of pain and
chronic disability in aging individuals. Articular cartilage
(AC) inflammation has often been attributed to OA
development as a secondary effect, because increased
matrix degradation and cell death occur under these con-
ditions [1-6]. Specifically, synovial TNFα and IL-1β have
been shown to drive matrix breakdown through their abil-
ity to upregulate cartilage catabolic enzymes as matrix* Correspondence: galiabl@ekmd.huji.ac.il; monad@ekmd.huji.ac.il
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stated.metalloproteinases (MMPs) and downregulate anabolic
matrix components [2,4-6]. To date, AC loss or damage in
OA is detected on radiography by measuring decreased
joint space width. However, radiographic evidence is seen
only after significant cartilage degradation has already
taken place. Hence early stages of OA may remain latent
and asymptomatic for many years. Therefore, there is a
pressing need for reliable new biomarkers and diagnostic
tests that can facilitate earlier diagnosis of OA, and inform
the prognosis, monitoring and therapeutic strategies for
chronic and disabling forms of the disease [7].
Of particular interest is the family of cysteine proteases,
cathepsins, which have been implicated in the pathogenesis
of OA and contribute to cartilage degradation [8-13]. Ex-
tensive studies in mice, guinea pig, canine and rabbit
models have shown a chondroprotective effect of cathep-
sin K inhibitors on OA pathology [14-16]. Cathepsintral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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structure by cleaving their triple helices and altering the
capacity of the fibers to withstand tensile forces [17].
Cathepsin K has thus been associated with OA, rheuma-
toid arthritis (RA) and osteoporosis pathogenesis [8].
Specifically, cathepsin K is actively secreted by resorbing
osteoclasts and therefore, also impacts the gross density
of bone. The fact that cathepsin K could be involved in
many prominent musculoskeletal diseases such as OA, RA
and osteoporosis [8,14-16] insinuates that it may not be a
distinct etiological component in OA pathophysiology.
While other cartilage matrix degrading enzymes such
as MMPs and A Disintegrin And Metalloproteinase with
Thrombospondin Motifs (ADAMTs) are active at neutral
pH, most of the lysosomal cathepsins are optimally ac-
tive at acidic pH. Nonetheless, pH levels have been re-
ported to drop in RA and OA superficial cartilage zones
and synovial fluid (SF) [9,18]. Both cathepsin B and S
have been reported to maintain their enzymatic activity
in a wide pH range (from 5.0 to 7.5), [12,19-21], and
therefore are likely to participate in cartilage extracellular
matrix (ECM) degradation [22]. Specifically, cathepsin B
was found to generate the CTX-II from the C-telopeptide
of collagen type II and cleave aggrecan between the G1
and G2 domains [23], while cathepsin S was reported to
display aggrecanase activity [24], suggesting they both
have a role in accelerated cartilage degradation [24,25]. In
addition to its extracellular targets in cartilage, cathepsin
B was found to mediate cleavage and inactivation of
SIRT1 (FLSIRT1) in response to pro-inflammatory stimuli,
thereby leading to reduced COL2A1 expression [12,26].
Furthermore, cathepsin B has displayed enhanced activity
in OA versus non-OA/normal cartilage and was thereby
envisioned to perpetuate OA pathophysiology in nu-
merous investigations [10-12,27,28]. On the other hand,
cathepsin S was recently shown to be secreted by chon-
drocytes stimulated with TNFα/IL1β [9], further sup-
porting its role in joint inflammation.
This research investigation sought to profile cathepsin B
and S activity in primary chondrocytes, explant cultures,
and serum and SF samples to examine if changes in
cathepsin activity correlate with OA severity. To profile
changes in cathepsin B and S activity we utilized a small
molecule activity-based probe (ABP) that covalently binds
to its target enzyme in an activity-dependent manner (see
Figure 1A). The covalent nature of binding of ABPs to
their enzyme targets leads to their retention in the active
site allowing for biochemical analysis of each of their
target enzymes simultaneously. ABPs can be attached to
various tags such as fluorescent tags, biotin or radio-
active markers that enable specific detection of their
target proteases. Here we utilize our published fluores-
cent ABPs GB123 comprised of an electrophilic acylo-
xymethyl ketone warhead that generates a specificcovalent modification to the active site cysteine of ca-
thepsins B, L and S. GB123 can freely penetrate cells
thereby targeting a larger pool of active intracellular and
extracellular enzymes resulting in high signals in vivo
detected non-invasively [29,30]. Furthermore, we have
published on cathepsin ABPs tagged with 64Copper that
can be suited for detection in humans [31]. Hence, using
such probes provides translational potential in non-
invasive imaging of the joints as well as bodily fluids.
Materials and methods
Human tissues
All procedures were performed with Hadassah Medical
Center Institutional Review Board approval and in accord-
ance with the Helsinki Declaration of ethical principles for
medical research involving human subjects. Formal writ-
ten informed consent was obtained from 30 donors with
OA, who were undergoing total knee arthroplasty (mean
age 72 years, mean body mass index (BMI) 31.5 kg/m2),
prior to obtaining articular cartilage samples from their
knee joints. Age-matched non-OA cartilage was obtained
from NDRI, Philadelphia.
Serum and synovial fluid were obtained from non-OA
donors and patients with early OA, late OA and RA, as
partly described previously [32], following institutional
approval by the local ethics committee of Justus-Liebig-
University of Giessen, and obtaining written informed
consent from all participants.
SF was obtained postmortem from the knee joints of 11
donors with no documented history of joint disease. The
average (av) age of the non-OA donors was 22.5 years
and the av BMI was 22.6. The control subjects were exam-
ined at the Institute of Forensic Medicine, Justus-Liebig-
University of Giessen. Serum samples were obtained from
10 healthy donors (av age 22.5 years, BMI 22.6, 40% male).
SF (total of 32 samples) and serum (total of 20 sam-
ples) were ranked for OA severity based on the macro-
scopic appearance of six cartilage surfaces [33], namely
the patella, trochlea, and medial and lateral femur and
tibia, using the Outerbridge scale [34]. Joints with an av
Outerbridge score ≤2 were classified as having early OA,
and joints with an av Outerbridge score of ≥2 were
classified as having late OA [33]. We collected serum
from early OA (10 patients, av age 47.3 years, av BMI
27.6, 70% male), SF from early OA (17 patients, av age
44.8 years, av BMI 26.8, 75% male), serum from late
OA (10 patients, av age 68.3 years, av BMI 28.2, 60%
male), SF from late OA (15 patients, av age 67 years, av
BMI 29.4, 69% male). SF was also collected from RA
patients (10 patients, av age 64.6 years, av BMI 27.3, av
serum C-reactive protein (CRP) 25.9 mg/L, 70% male)
who were diagnosed by a board-certified rheumatolo-
gist, according to the American College of Rheumatol-
ogy (ACR) 1987 revised criteria [34].
Figure 1 Activity-based probe (ABP) targets active cathepsins in TNFα/IL1β-stimulated chondrocytes. (A) ABP binding mechanism.
Illustration shows the general structure of an APB with a triangular reactive moiety. Covalent modification of the target protease results in
production of a fluorescently labeled enzyme. (B) Protein extracts from TNFα/IL1β-treated and untreated chondrocytes labeled with GB123
with or without pretreatment of cathepsin inhibitor GB111-NH2, as indicated (n = 4) with quantification of band intensity (Image J software)
below. (C) Protein extracts from IL1β-treated and untreated chondrocytes labeled with GB123 with or without pretreatment of cathepsin inhibitor
GB111-NH2, (n = 4) with quantification below. (D) Protein extracts from TNFα/IL1β-treated and untreated chondrocytes were labeled with GB123
and immunoprecipitated with cathepsin S antibody (n = 4). Below, a gel showing protein extracts incubated with or without CA-074 (selective
cathepsin B inhibitor) and labeled with GB123. The long chain of active Cathepsin L was detected between 20 and 25 kDa. (E) Time-course
experiments (50 ng/mL TNFα and 5 ng/mL IL1β) with GB123 labeling; experiment duration indicated above the gel (n = 4). (F) Dose response
experiments (24-h incubation), with GB123 labeling, performed for cytokine concentrations (ng/mL);(n = 4). Gels were scanned (Typhoon scanner
Excitation/Emission 630/670 nm) to detect fluorescent-labeled active cathepsin bands. aCathB, active cathepsin B (32 kDa); aCathS, active cathep-
sin S (25 kDa); IP, immunoprecipitation, Unt, untreated. Band intensity plots (image J software) show SD around average data point. Statistical ana-
lysis was by non-parametric Mann-Whitney analysis, considering P <0.05 statistically significant.
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con filter (Millipore, Billerica, MA, USA) and then la-
beled with our published cathepsin activity-based probe,
GB123 (specified below) at 2 μM concentration for
3 hours. Reaction was stopped with sample buffer and
24-μg proteins were analyzed by SDS PAGE. Synovial
fluids, 10 μL, were labeled with 5 μM GB123 for 3 hours,
and then the reaction was stopped with sample buffer and
analyzed by fluorescent SDS PAGE scanning using a
Typhoon flatbed scanner (GE Healthcare: Bio-Sciences
AB, Uppsala, Sweden, Excitation/Emission 630/670 nm).
GB123 fluorescently labeled cathepsins B, L and S bands
represent enzyme activity in proportion to band inten-
sity, not enzyme quantity, as described previously [30].Cells, tissue cultures and reagents
Freshly isolated chondrocytes were obtained from intact and
degenerative regions of OA-derived cartilage, dissected and
subjected to 0.25% Trypsin-EDTA solution (Beit-Haemek
Kibutz, Israel) at 37°C, 60 minutes rotation, then washed with
PBS twice and overnight digested with 0.02% collagenase
(Worthington Biochemical, Lakewood, NJ, USA) in DMEM
containing 10% FCS and 1% Penicillin-streptomycin (Biological
Industries, Beit-Haemek Kibutz, Israel). On the following day
the cells were filtered through 40-μm nylon mesh,
washed twice with PBS and lysed in radioimmunoprecipita-
tion assay (RIPA) buffer (PBS, 1% NP-40, 0.5% Deoxycholate
(DOC), 0.1% SDS). Proteins were quantified using the
Bradford assay and 50 μg of proteins from each sample were
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DTT, 100 mM Acetate) and with 1 μM GB123 (final con-
centration) for 1 hour at 37°C for cathepsins labeling. Intact
cartilage (IC) and degraded cartilage (DC) supernatants
were treated with collagenase and directly labeled with
1 μM GB123 for 5 hours at 37°C. Supernatants were fil-
tered using a 50-kDa cutoff amicon filter (Millipore,
MA), proteins were precipitated with 70% acetone at
−80°C. On the following day the samples were centri-
fuged for 15 minutes at 14,000 rpm, pellets were resus-
pended in 35 μl RIPA buffer, and 30 μg of proteins were
separated by SDS-PAGE.
To test if cathepsin S or B were modified in the presence
of collagenase digestion media, 0.5 μg recombinant hu-
man cathepsin B or S [35], were incubated (1h or over-
night) with collagenase media at 37°C and analyzed for
cathepsin activity and protein levels. GB123 potency to-
wards human cathepsin B, K and S was determined by la-
beling 0.5 μM active recombinant enzyme with
1 μM GB123 for 1 hour as indicated above.
Human chondrocytes were isolated from intact cartil-
age zones as indicated above and cultured to reach 90%
confluence (passage 0 or 1) in DMEM media containing
10% FCS, 1% Penicillin-streptomycin at 37°C, and 5% CO2.
Medium was then replaced with BIO-MPM (Biological In-
dustries), a defined and enriched growth medium contain-
ing Penicillin-streptomycin with or without 50 ng/mL
TNFα and/or 5 ng/mL IL1β (PeproTech, Rockey Hill, NJ,
USA) for 24 hours. Cells were pretreated with a specific ca-
thepsin inhibitor GB111-NH2 [36] or vehicle for one hour
prior to direct labeling with 5 μM GB123. Then the cells
were lysed in RIPA buffer and medium proteins were pre-
cipitated with 70% acetone as indicated above. Samples
were analyzed by SDS PAGE or immunoprecipitated (IP)
with cathepsin S antibody (R&D Systems, Minneapolis,
MN, USA, cat#AF1183). To examine cathepsin B labeling
(that is, 32 kDa), cells were lysed in RIPA and an equal
amount of proteins were pre-incubated for 1 hour
with 5 μM CA-074 (Sigma Aldrich, St Louis, MO, USA), a
specific cathepsin B inhibitor, or DMSO vehicle at 37°C.
Then 1 μM GB123 was added for an additional hour at
37°C. The reaction was stopped by adding sample buffer,
followed by SDS PAGE. All samples were separated on a
12.5% SDS PAGE gel and scanned for fluorescence
using a Typhoon flatbed scanner.
Three-dimensional alginate cultures were obtained
with passage-1 human chondrocytes, treated with cyto-
kines and processed for mRNA isolation, as previously
described [37]. Explants cultures were obtained from
intact or degenerated regions of cartilage derived from
OA patients and dissected perpendicular to subchon-
dral bone into round 4-mm-diameter cartilage tissue
samples (weight 6 to 9 mg each) and analyzed for
GB123 fluorescence.Immunoblot analysis
Cell pellets were suspended with RIPA lysis buffer with
complete inhibitor cocktail (Roche, Basel, Switzerland), quanti-
fied with Bradford reagent (Sigma-Aldrich, St Louis, MO,
USA), run on standard 10% SDS PAGE gels and transferred
to polyvinylidene fluoride (PVDF) membranes for immuno-
blot (IB). The following antibodies were used for IB: β-actin
(Santa Cruz Biotechnology, Dallas, Texas, USA; cat#47778),
cathepsin S (Abcam, Cambridge, UK cat#134157), cathepsin B
(Abcam cat# ab58802); Secondary antibodies: Anti-Mouse-
alkaline-phosphatase (AP)-conjugated (Sigma-Aldrich, cat#,
A3562), Anti-rabbit-AP conjugated (Sigma-Aldrich, cat#,
A3687). All IBs were scanned at high resolution and band in-
tensity was determined using Image J software (NIH, USA).
After subtracting the background, each band was normalized
to the corresponding housekeeping protein (that is, β-actin)
appearing on the blot. Band intensity was presented in arbi-
trary units (A.U.) adjacent to the representative IB.
Fluorescent labeling of explant sections
Explants were embedded in optical cutting temperature
(OCT) and snap-frozen in liquid nitrogen prior to cryosec-
tion; and 10-μm sections were obtained and embedded on
glass slides, fixed with 4% paraformaldehyde (diluted with
PBS) for 30 minutes at 4°C, followed by washing three
times with PBS for 5 minutes. Sections were labeled with
GB123 (1 μΜ, 37°C, 30 minutes) with or without pre-
incubation with GB111-NH2 inhibitor (1 μΜ, 37°C, 30 mi-
nutes). Slides were washed twice with PBS and mounted
with 4′: 6-diamidino-2-phenylindole (DAPI)-fluoromount-
G (SouthernBiotech, Birmingham, AL, USA). The stained
sections were visualized under an inverted fluorescent
microscope with DAPI and Cy5 lasers and filters (Olympus
FV10i inverted microscope, Tokyo, Japan).
Immunohistochemistry
IC/DC tissues were fixed in 4% formalin and decalci-
fied for 3 days in 4% formic acid/4% HCl and embed-
ded in paraffin: 5-μm sections were digested with
1 mg/mL Hyaluronidase (Sigma Aldrich, St Louis,
MO, USA) in PBS (pH = 6) for 1 hour at 37°C, and
stained with anti-cathepsin S antibody and DAB sub-
strate kit (Zytomed systems, Berlin, Germany).
Quantitative polymerase chain reaction (qPCR) analysis
mRNA was isolated using RNeasy mRNA purification
columns (Qiagen, Hilden, Germany). cDNA was then
prepared using the OneStep RT-PCR kit according to
the manufacturers guidelines (Invitrogen Carlsbad,
CA, USA). Real-time PCR reactions were performed
using an ABI qPCR model 7300 or 7900 (Applied
Biosystems, Foster City, CA, USA) with purified
samples containing a Syber Green mix (Applied
Biosystems) in accordance to the manufacturers’
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the following human genes: Cathepsin S(CAT), forward:
5′-GACTGGAGAGAGAAAGGGTGTGTT-3′, reverse:
5′-CAGCTTTCCTGTTTTCAGCTTCA-3′, hβ2MG-




All experiments were performed on multiple donor sam-
ples as indicated in each figure legend. Data points rep-
resent average and standard deviation, unless otherwise
indicated. Statistical analysis was obtained using non-
parametric Mann-Whitney analysis (two-tailed). P-values
for plotted data ≤0.05 were considered statistically sig-
nificant. Correlation between serum and SF cathepsin
bands (imageJ, A.U.) were drawn for age per clinical
group (that is, healthy/non-OA, early OA, late OA and
RA) and amongst all groups, based on the Pearson coef-
ficient (1 ≥ p ≥ −1), considering P ≤0.05 to be statistically
significant. The values were also assessed by linear re-
gression (R2).
Results
Detection of enhanced cathepsin S activity in
TNFα/IL1β-treated chondrocytes
We set out to investigate the cathepsin activity in OA by
applying our previously developed fluorescently labeled
cathepsin ABP, GB123, [30]. This ABP was designed to
covalently attach to active cathepsins B (32 kDa), L (ap-
proximately 22 kDa) and S (25 kDa) (see illustration in
Figure 1A) [36]. Surprisingly, we found that GB123 can
label cathepsin K (25 kDa) as well, but significantly weaker
compared to cathepsins B and S (Additional file 1).
GB123 was pre-incubated with chondrocyte extracts,
which were stimulated or unstimulated with TNFα and
IL1β. A more than four-fold increase in cathepsin S ac-
tivity was detected (25-kDa band), without detectable
changes in cathepsin B activity (Figure 1B). While ca-
thepsin S activity was significantly enhanced, cathepsin
B did not show a significant increase upon IL1β stimuli
alone (Figure 1C). To identify the GB123-labeled bands
we immunoprecipitated the labeled lysates with a cathep-
sin S antibody, and similarly, the pulled-down protein
showed an increase in activity with TNFα/IL1β treatment
(Figure 1D). Although the 25-kDa band may contain ac-
tive cathepsin K the IP experiment confirmed the eleva-
tion in cathepsin S activity. To examine the exact band of
cathepsin B, we subjected cell lysates to a specific cathep-
sin B inhibitor (CA-074) and labeled them with GB123
(Figure 1D, lower panel). The results confirm that the
32 kDa band represents active cathepsin B, given that it
disappears when treated with the inhibitor without
impacting the activity of cathepsin S (25 kDa). Overall,while no dramatic changes in chondrocyte cathepsin B
activity (32 kDa) were observed, enhanced cathepsin S
activity was clearly seen in TNFα- and/or IL1β-stimulated
chondrocytes. These data are in line with time course and
dose response experiments (Figure 1E and F, respectively),
showing that cathepsin S is responsive to increasing cyto-
kine dose. As cathepsin L activity (the band between the
20- to 25-kDa protein ladder) was variable, we chose to
focus on cathepsins B and S, which exhibited consistent
responsiveness to stimuli.
Enhanced secretion of cathepsins B and S in conditioned
media of cytokine-treated chondrocyte cultures
Conditioned medium from TNFα/IL1β-treated chondro-
cytes was collected and labeled with GB123. Enhanced
cathepsin B and S activity was detected in TNFα/IL1β-
conditioned medium (Figure 2A), with a similar trend
for cathepsin S upon IL1β stimuli (Figure 2B). These data
support the idea that pro-inflammatory stimuli contribute
to catabolic enzyme secretion into the extracellular milieu
in the cartilage.
Enhanced cathepsin activity in degenerative cartilage
To further investigate the cathepsin activity within differ-
ent regions of OA cartilage, IC and DC regions were ana-
lyzed. The surrounding cartilage matrix was disintegrated
by collagenase digestion and media and freshly isolated
cells were subsequently labeled with GB123. While both
cathepsins B and S showed enhanced activity in cell ex-
tracts from coarse DC regions (Figure 3A), only cathep-
sin S appeared enhanced (3-fold) in DC cartilage media
(Figure 3B), as judged by its presence in collagenase diges-
tion media. To examine whether treating cartilage tissue
with collagenase modifies cathepsin activity, we incubated
purified recombinant human cathepsins B and S separately
with collagenase media (Figure 3C and D), as previously
done with IC/DC samples. Only cathepsin B exhibited
reduced activity when incubated with collagenase over-
night (30% reduction in activity), while no changes were
observed for cathepsin S activity (Figure 3C). These results
fit well with the complete degradation of cathepsin B ob-
served by IB after overnight incubation with collagenase,
(Figure 3D). It is likely that the absence of active cathepsin
B in DC collagenase digestion-media is due to its suscepti-
bility to collagenase, which was significantly enriched in
our digestion media.
Cryosections of IC and DC explants were stained with
GB123 to visualize the regions with enhanced cathepsin
activity. An inhibitor control (GB111-NH2) was used to
verify the activity-dependent staining of the cathepsins
(Figure 3E and F). Cells within DC regions showed
markedly increased cathepsin activity compared to IC
regions, observed by intense red fluorescence of the cells
and the surrounding matrix.
Figure 2 Cathepsin activity in conditioned media of human chondrocytes and explant cultures. Human chondrocytes were isolated from
intact regions of osteoarthritis (OA)-derived cartilage and plated at passage 0. Following confluence the cells were treated with (A) 50 ng/mL
TNFα and 5 ng/mL IL1β for 24 h or (B) 5 ng/mL IL1β. Conditioned media were labeled with GB123, concentrated and run on PAGE, and labeled
cathepsins were detected by on gel-fluorescent scan (n = 4). Plots of band intensity (imageJ software) show standard deviation surrounding an
average data point. Statistical analysis was obtained using non-parametric Mann-Whitney analysis, assuming P <0.05 to be statistically significant.
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filed within the superficial- and midzone-cartilage region
samples of DC and IC stained with GB123 (Figure 4).
Interestingly, articular cartilage ECM showed a signifi-
cant (2-fold) increase in activity within the first 300-μm
depth of DC samples, while this was not detected in IC
(Figure 4B, left plot). Quantifying the fluorescence of cell
clusters within superficial and midzone articular cartil-
age (that is, up to 1000 μm in depth) showed a 40% in-
crease in cellular cathepsin activity within DC versus
adjacent IC tissues, using GB123 labeling.
Enhanced cathepsin S in pro-inflammatory conditions and
during cartilage degeneration
Having shown that cathepsin B and S activities were
enhanced (Figures 1 and 2), we next wanted to validate
these findings also at mRNA level using monolayer and
alginate microencapsulated human chondrocytes sub-
jected to TNFα/IL1β stimulation (Figure 5A). We found
that in chondrocytes stimulated with TNFα/IL1β ex-
pression of cathepsins S and B was enhanced (CATS/B),
(Figure 5A; left panel). However, three-dimensional
chondrocyte cultures showed mRNA increase only forCATS (Figure 5A; right panel). A significant increase in
CATS expression was also observed in freshly isolated
OA chondrocytes as compared to normal/non-OA chon-
drocytes (Figure 5B), which was similar to the significant
increase in CATB expression that we previously reported
[38]. In general, elevation in cathepsin S mRNA and pro-
tein was more pronounced than that observed under the
same conditions for cathepsin B. In line with these results,
the protein level of cathepsin S was also found elevated
(>2-fold) in TNFα/IL1β chondrocytes, (Figure 5C), which
is also apparent in immunohistochemistry of IC/DC sec-
tions (Figure 5E, left panel). Consistent with our previous
reports [38], cathepsin B was also increased upon cytokine
treatment (Figure 5C), but showed a less intense color-
ation within ECM of DC sections as compared to that ob-
served for cathepsin S staining (Figure 5E, middle panel).
The reduced coloration of cathepsin B in cartilage ECM
may be due to its susceptibility to the presence of collage-
nase in OA tissue, as we previously showed in Figure 3.
On the other hand, cystatin C (a natural cathepsin inhibi-
tor) was not affected by cytokine stimuli of chondrocytes
(Figure 5D); however, immunochemistry displayed more
intense coloration within ECM of DC compared to IC
Figure 3 Cathepsin activity is increased in degraded cartilage from osteoarthritis (OA) patients. Intact and degraded cartilage (IC and DC)
derived from end-stage OA patients were analyzed with GB123 for (A) cathepsin activity in freshly isolated chondrocyte lysates and (B) degraded
cartilage media, which was obtained following a collagenase digestion procedure (24 h, 37°C). Samples were treated with GB123 and subjected
to SDS PAGE and fluorescence visualization as in Figure 1 (n = 4). The heavy chain of active Cathepsin L was detected between 20 to 25 kDa (A).
(C) Recombinant cathepsin B (right) and cathepsin S (left) were treated for 24 h with collagenase digestion media (0.02%), labeled with GB123
and analyzed as in Figure 1 (n = 3). (D) Enzymes were analyzed by SDS-PAGE and immunoblotted with cathepsin B or S antibodies (n = 3).
(E, F) Cryosections of IC/DC (5 μm-thick) stained with 4′: 6-diamidino-2-phenylindole (DAPI) (blue fluorescence for nuclei), GB123 (red fluorescence
for cathepsin activity), with or without pre-incubation with the cathepsin inhibitor GB111-NH2 (n = 4). Increased cathepsin activity in DC versus
IC regions is clearly observed. Images taken with 60-times magnification (E) and with 10-times magnification (n = 5) (F). Plots of band intensity
(panels A and B; imageJ software) show SD surrounding an average data point. Statistical analysis was by non-parametric Mann-Whitney
analysis, assuming P <0.05 to be statistically significant.
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Figure 4 Profiling cathepsin activity in osteoarthritis (OA) articular cartilage. Cryosections of intact cartilage (IC)/degenerated cartilage (DC),
5-μm thick, stained with GB123 and 4′: 6-diamidino-2-phenylindole (DAPI) then analyzed for cathepsin activity using imageJ intensity software. (A)
Representative phase images overlaid with GB123 fluorescence, sections of IC and DC at 60- and 10-times magnification (n = 5). Red and blue
fluorescence are Cy5 (GB123) and DAPI, respectively. (B) Cathepsin activity as a function of cartilage distance from the articular surface (that is,
superficial zone) and up to 1.5 mm deep (left panel): right panel, overall quantification of cathepsin activity surrounding chondrocyte clusters
(that is, cartilage extracellular matrix (ECM)). Plots of band intensity (image-J software) show SD surrounding an average data point. Values were
generated by subtracting the background from images of cathepsin-stained cell clusters. Statistical analysis was by non-parametric Mann-Whitney
analysis, assuming P <0.05 to be statistically significant.
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of cathepsin B/S compared to cystatin C may partly ex-
plain the reason for the enhanced cathepsin activity moni-
tored with GB123 (Figure 4).
SF and serum analysis for OA, RA and non-OA samples
using GB123
To test if cathepsin activity detected by ABP could serve
as a marker for severity of OA and joint inflammation we
analyzed serum samples of non-OA cadavers (N), and
early OA (E) and late OA (L) patients, (Figure 6A). Using
GB123 labeling we monitored cathepsin B and S bands,
based on our in-vitro observations, their expected selectiv-
ity to the probe and characterized molecular weight.
Furthermore, we confirmed that GB123 labels non-OA
human SF in an activity-dependent manner, which was
validated by pretreatment with a cathepsin inhibitor,
GB111-NH2 (Additional file 2: Figure S2).
While cathepsin S is significantly more active in all
OA sera than cathepsin B, only cathepsin B was signifi-
cantly enhanced in sera of early OA versus late OApatients. Cathepsin B also showed a similar increase be-
tween non-OA and late OA sera, however, this increase
was statistically insignificant. Given the activity of both
cathepsins increased at late stages of OA, we next
assessed their activity in SF from non-OA donors and
patients with early OA, late OA and RA (Figure 6B).
Among all the groups, cathepsin S activity was higher
as compared to cathepsin B, similar to the trend observed
in sera. Moreover, cathepsin S activity was substantially
higher in RA as compared to early OA, late OA and non-
OA samples. On the other hand, cathepsin B activity was
enhanced with a higher statistical significance amongst
the various OA stages than that of cathepsin S. It is there-
fore concluded that both cathepsins are equally important
for diagnosing OA in SF. While cathepsin B activity may
indicate the severity of OA, cathepsin S could exclude RA,
since it is highly active in RA SF. With respect to OA dis-
ease severity, cathepsin B appears to exhibit delayed serum
accumulation compared to equivalent levels in SF.
To assess if cathepsin activity is affected by age
(Additional file 3), we carried out correlation assays for
Figure 5 Cathepsin S/B expression and activity is enhanced under cytokine stimulation. (A) Fold-increase in cathepsin S and B (denoted as
CATS/B) expression in cytokine (that is, TNFα and IL1β) stimulation of monolayer cultures (2D) and chondrocyte cultures in alginate microbeads
(3D), normalized to GAPDH and untreated cells. For treated 3D cultures cytokines were added to the crosslinked alginate suspension containing
chondrocytes. Unt indicates untreated controls. (B) Human chondrocytes were isolated from non-OA/normal and osteoarthritis (OA)-diagnosed
donors, mRNA was isolated from samples and analyzed for CATS expression. (C) Protein extracts from human OA-derived chondrocytes (passage
0) that were treated or untreated with cytokines were immunoblotted for cathepsin S and B (D) and cystatin C. Band quantification plot beneath
each blot in (C) and (D). (E) Left panel shows immunohistochemistry (IHC) of IC/DC sections stained for cathepsin S, middle panel for cathepsin B
and right panel for cystatin C (n = 3). Statistical analysis was by non-parametric Mann-Whitney analysis, assuming P <0.05 to be statistically significant.
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upper graphs for serum and SF) and within each group (B,
Table, Additional file 3). The data suggest that age doesnot correlate significantly with changes in cathepsin S and
B activity, based on P-values of the Pearson coefficient
(Pc). Nonetheless, analysis of cathepsin S activity in SF
Figure 6 (See legend on next page.)
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Figure 6 Profiling cathepsin activity in serum and synovial fluid of osteoarthritis (OA) patients. (A) Non-OA/normal (N), early OA (E) and
late OA (L) sera were labeled with GB123, separated by SDS PAGE, scanned for fluorescence and quantified for band intensity, following subtracting
gel background (n = 10 per group). (B) non-OA (N) (n = 11), early OA (E) (n = 17), late OA (L) (n = 15) and rheumatoid arthritis (RA) (n = 10) synovial
fluid (SF) were labeled with GB123, and analyzed similar to A. Plots of band intensity (imageJ software) show SD surrounding an average data point.
Statistical analysis was by non-parametric Mann-Whitney analysis, assuming P <0.05 to be statistically significant. Within each plot a table depicts statis-
tical significance (*P <0.05, **P <0.01, ***P <0.001) for cathepsin B and S activity upon comparison of the different groups.
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reduced with age, which coincides with the reduced
cathepsin activity observed in advanced age reported
by Bayliss et al., 1978 [28]. These data indicate that ca-
thepsin S may be a good marker for non-invasive imaging
of RA joints only at early ages (40 to 50 years), when OA
signs due to cathepsin B are not evident (Figure 6B).
Based on these preliminary findings, it appears that non-
invasive joint imaging to detect cathepsin activity in SF
may be a good indicator of early signs of OA.
Discussion
The unique structure of cartilage ECM plays a key role
in the load-bearing capacity of the AC. It is composed of
collagen type II, IX and XI, which provide tensile force
to the tissue [39]. In addition, proteoglycans, especially
aggrecan, provide a hydrated gel-like medium enabling
AC resilience to load-induced deformation. During OA,
much of the cartilaginous ECM is degraded by catabolic
enzymes namely ADAMTS’s and other MMPs [1,2,6].
Amongst the catabolic enzymes involved in cartilage break-
down, the lysosomal cysteine proteases, the cathepsins
have also been shown to contribute to cartilage ECM deg-
radation [8-11,22]. Interestingly, OA cartilage and SF have
acidic pH [9,18], which may favor catabolic activity of lyso-
somal cysteine proteases.
Lysosomal cysteine proteases activity has been addition-
ally linked to internal pathways of chondrocyte apoptosis
and gene regulation related to OA pathology via regula-
tion of SIRT1 activity [12,26,40,41]. Here we used an ex-
perimental approach wherein various chondrocyte cultures
were stimulated with pro-inflammatory cytokines TNFα and
IL-1β resulting in a prominent increase in cathepsin S and B
activity. Among these cathepsins, cathepsin S was more sus-
ceptible to changes in cytokine stimulation and their doses
and relatively resistant to collagenase breakdown, which
may be enhanced in diseased cartilage. Despite the fact that
the activities of both cathepsins were enhanced in DC chon-
drocytes, active cathepsin S showed a moderate increase in
late OA serum with more abundant activity levels in RA SF.
On the other hand, increased cathepsin B activity was ob-
served in late OA serum and amongst the different OA se-
verities within SF. Collectively, these data support the idea
that cathepsin S is involved in acute inflammatory condi-
tions of cartilage, in agreement with the earlier study ofPožgan et al. (2012), [13]. In addition, previous reports by
Hou et al. (2002) demonstrated that cathepsin S is pro-
nounced in macrophage-like synoviocytes supporting the
concept that it possesses a role in antigen presentation as
well as matrix degradation of synovial tissues [42]. Ca-
thepsin S also serves as a microglial mediator exerting in-
creased pain sensitivity [43]. Clark et al., (2012) showed
that inhibiting cathepsin S significantly reduces pain
perception and attenuated microglial response in a
collagen-induced arthritis rat model [44]. Given that the
immune-related pathogenesis of RA involves pronounced
synovial infiltration and synovitis, which is less pronounced
in OA pathophysiology, cathepsin S activity may be less re-
sponsive than cathepsin B to the pathogenesis of OA, in
line with our observations.
Superficial regions of severely degraded cartilage
showed more than a 2-fold increase in cathepsin activity
using ABP labeling. These data therefore support the
idea that the cathepsins are involved in ECM processing
and are regulated by factors in the SF [22]. Based on
these observations and our analysis of SF we envision
that imaging techniques using modified ABPs for better
joint penetration may be suitable means for early detec-
tion of OA, rather than serum analysis with these
probes. Furthermore, fluorescently labeled ABPs were
already converted to 64Copper labeled cathepsin positron
emission tomography (PET) probe [31] to improve de-
tection in deeper tissues. Such means could provide add-
itional insight into the joint state using non-invasive
imaging techniques based on PET. Upon systemic ad-
ministration, ABPs are envisioned to access the synovial
space through its vasculature, potentially providing a
signal-to-background ratio indicative of the cathepsin
activity in the joints, which could be translated to OA
severity within the joint.
There have been recent reports on molecular imaging of
diseased joint with fluorescently labeled small molecules
in an attempt to image OA [45-47]. These reports prove
that imaging reagents may enter and accumulate in the
diseased joint and could also be monitored non-invasively
in mice. Thus, our ABP could potentially accumulate in
OA joints when applied in vivo. We find the ABPs attract-
ive imaging reagents because they covalently bind their
target in vivo, thereby accumulating in the diseased area,
such as SF, and allow for non-invasive imaging [28].
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chemical analysis of their targets, enabling careful moni-
toring of the various cathepsins in vivo.
Conclusion
In summary, our analysis of SF using ABP show that ca-
thepsin B is more likely involved in OA pathogenesis than
cathepsin S and that their differential detection using ABP
labeling could provide a measureable diagnostic tool for
detecting RA or early stages of OA. Overall, based on our
results, we envision that development of robust and
sensitive imaging procedures based on ABPs will enable
early detection of OA and RA as well as provide means
for testing the efficacy of disease-modifying drugs to
treat joint diseases.
Additional files
Additional file 1: Recombinant human cathepsins (final 0.5 μM
active enzyme per lane; reference [35]), were diluted with acetate
buffer and labeled with 1 μM of GB123 for 1 hour at 37°C. Reaction
was stopped by adding sample buffer and boiling the samples at 95°C
for 5 minutes. Samples were loaded on a 12.5% SDS PAGE gel and
scanned with a Typhoon scanner as in Figure 1.
Additional file 2: Osteoarthritis (OA) synovial fluid, 5µl, were
diluted in acetate buffer 1:1 and passed through a syringe with
21-G, 27-G, and 30-G needles. Samples were then filtered through a
50-kDa cutoff amicon and spun at 14,000 g at 18°C for 30 minutes.
Samples were treated with dimethyl sulfoxide (DMSO) vehicle or
10 μM GB111-NH2 cathepsin inhibitor [36], for an hour at 37°C. After
pretreatment, the samples were labeled with 5 μM GB123 for one hour
at 37°C. Reaction was stopped by adding 4 × sample buffer and boiled
for 10 minutes. Samples were separated on a 12.5% SDS PAGE and
scanned for Cy5 fluorescence with a Typhoon scanner.
Additional file 3: Correlation of age with cathepsin S (CTSS) and B
(CTSB) activity on serum and synovial fluid (SF): serum and SF
samples were processed and run as indicated in the Materials and
methods section. All gels were scanned in high resolution and band
intensity was determined using ImageJ software. After subtracting the
background, net band intensity (A.U.) corresponding to either cathepsin
S or B was correlated with the donors age amongst all groups (A)
and within each group (B, Table). Correlation between serum and SF
cathepsin bands were based on Pearson coefficient test (Pc; 1 ≥ p ≥ −1),
considering Pc ≤0.05 to be statistically significant. Pearson correlation
coefficient measures linear correlation between two variables, wherein a
P-value of 1 indicates total positive correlation, 0 indicates no correlation,
and −1 is total negative correlation. The values were also assessed for
linear regression (R2), as indicated.
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